Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:36:29.356Z.
Calculation as of: 2026-10-06T13:36:29.356Z.
Quote observation: 2026-10-06T13:34:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$258.93M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.75M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.05M
EV/FCF Ratio
442.97x
TTM Avg
210.95x
3Y Avg
227.91x
5Y Avg
182.13x
Market Cap
$260.75M
EV/FCF Ratio
N/A
TTM Avg
48.59x
3Y Avg
48.59x
5Y Avg
48.59x
Market Cap
$251.01M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$249.24M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $258.93M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.75M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | 442.97x | 210.95x | 227.91x | 182.13x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $260.75M | N/A | 48.59x | 48.59x | 48.59x |
| Century Therapeutics, Inc. (IPSC)vs › | $267.99M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $247.47M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.01M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $272.75M | N/A | 4.58x | 4.76x | 4.76x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.24M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $247.60M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
